Hemab's Debut: A Phase III the FDA Didn't Ask For
On its first ever earnings call, a $1.8B rare-disease biotech chose a single-arm pivotal trial over the FDA's preferred randomized design — and staked the equity story on two programs still years behind it.
COAG · Earnings Call · 2026-11-10
The first call is the only call
Hemab Therapeutics went public in May 2026 and used its inaugural quarterly call this week to compress about three years of normal biotech narrative into twenty minutes: a pivotal trial initiated, three data readouts dated, a first clinical dataset in a second indication, and a candid disclosure that the FDA had asked for something the company decided not to give it. There is no prior transcript to hold this management team against — the company's entire curated keyword history is a single quarter, so everything here is new by construction. That makes the exercise simpler and, oddly, more revealing: with no baseline of its own, Hemab's language can only be benchmarked against the rest of the market, and against the logic of its own trial design. The lexicon that surfaced from this call reads less like a commercial story than like the minutes of a regulatory negotiation. Alongside the program names — SOLARA, sutacimig, HMB-002, HMB-003 — the highest-momentum terms were variability, controlled trial, single arm, and eligibility criteria. For a company whose lead asset has no approved competitor, that is exactly backwards from what you would expect a debut call to sound like.A pivotal trial in the FDA's blind spot
The news itself is real. Monday brought initiation of SOLARA, a Phase III in Glanzmann thrombasthenia — roughly 75 patients, aged 12 to 70, at least four treated bleeds in the prior year, a 24-week run-in followed by 48 weeks of once-weekly subcutaneous dosing at 0.2 mg/kg. It is, per management, the first pivotal trial of a subcutaneous prophylactic in the disease. CEO Benny Sorensen framed the gap bluntly: “There is no approved prophylactic treatment and care today is reactive rather than preventive.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 In the Glanzmann's 360 natural history study cited on the call, 88% of participants reported at least one bleed in the previous week. But the design is a single-arm, open-label study with each patient as their own control, and the company volunteered that the FDA recommended a randomized controlled trial instead. Sorensen's read: “I think when they are saying recommend consider, that is probably for good order.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 He then asserted "the risk is very low here." That is the central tension of this report, and it is not a small one. The company's own Phase II extension — 34 participants, median 6.9 months of exposure, up to 15.9 months — reduced mean high-intensity annualized treated bleed rates by 62%, and roughly 80% in the low-dose weekly cohort. Those are strong numbers. But the same dataset is what management uses to justify avoiding randomization, because the treated bleed rate is so noisy that a parallel-arm design risks being unreadable at this population size. The argument cuts both ways: the variability that makes randomization impractical is also what an intra-patient comparison must survive across dozens of heterogeneous sites.Sorensen leaned on precedent — Vonvendi and Wilate in Von Willebrand disease, Hemlibra-adjacent HYMPAVZI in hemophilia A, Tretten in Factor XIII deficiency — and the company holds Fast Track Designation plus Breakthrough and Orphan designations, which matters: that exact regulatory status was one of the better-performing themes in the market's 90-day tape, with a cluster of rare-disease names (LLY, IOVA, ARWR, BIIB, VIR, LGND) up double digits on it. Approval pathways, not just data, are being paid for right now. One small tell: asked what the trial's top weight cutoff was, the CEO replied, “I forgot what the top weight range is in the eligibility criteria.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 Defensible — the details were going up on clinicaltrials.gov — but on the day you announce your first pivotal trial, and after three Grade 2 thromboembolic events in higher-exposure cohorts forced a dose cut to 0.2 mg/kg, weight eligibility is not an administrative footnote.When we do a Phase II trial in about 15, 16 sites, you get that variability. When we dial it up to a pivotal trial with approximately 75 patients enrolled across multiple countries, multiple sites, variability is rarely going down. It is more likely to stay the same.